Acurx Pharmaceuticals Inc. $(ACXP)$, a late-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2025. The company posted a net loss of $2.2 million for the three months ended June 30, 2025, compared to a net loss of $4.1 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $4.4 million, a decrease from the net loss of $8.5 million reported for the same period in 2024. The company successfully executed a warrant inducement transaction, resulting in gross proceeds of approximately $2.7 million, with net proceeds of $2.5 million after deducting fees and transaction expenses. Acurx Pharmaceuticals continues its multi-step approach to raising capital through various financings, warrant inducements, and public-private partnership opportunities. In June, significant progress was made with the publication of Phase 2b clinical trial data for ibezapolstat in C. Difficile infection in the Lancet Microbe, a leading microbiology research journal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.